# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Explore the use of Amgen's Blincyto in treating severe systemic sclerosis, shedding light on Cullinan Therapeutics' CLN...
Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today a...
Shares of The Travelers Companies, Inc. (NYSE: TRV) fell sharply during Wednesday’s session following first-quarter earnings.
BTIG analyst Kaveri Pohlman maintains Cullinan Oncology (NASDAQ:CGEM) with a Buy and raises the price target from $20 to $30.
U.S. stocks were lower, with the Dow Jones index falling over 50 points on Wednesday.